Sunshine Biopharma, Inc. (NASDAQ:SBFM) Sees Significant Decrease in Short Interest

Sunshine Biopharma, Inc. (NASDAQ:SBFM) saw a large decrease in short interest in December. As of December 15th, there was short interest totalling 474,300 shares, a decrease of 14.6% from the November 30th total of 555,600 shares. Based on an average daily volume of 660,100 shares, the short-interest ratio is currently 0.7 days. Approximately 23.7% of the company’s shares are short sold.

Sunshine Biopharma Stock Performance

Shares of NASDAQ:SBFM traded up $0.14 during trading on Tuesday, reaching $2.95. 95,285 shares of the stock traded hands, compared to its average volume of 264,781. Sunshine Biopharma has a 52-week low of $2.11 and a 52-week high of $582.00. The stock has a market cap of $3.61 million, a P/E ratio of -0.02 and a beta of 1.42. The stock has a 50-day moving average of $2.80 and a two-hundred day moving average of $2.18.

Sunshine Biopharma (NASDAQ:SBFM) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $9.00 by ($9.94). Sunshine Biopharma had a negative net margin of 12.82% and a negative return on equity of 17.89%. The business had revenue of $8.44 million for the quarter.

Analyst Upgrades and Downgrades

Separately, Aegis restated a “buy” rating and set a $15.00 price target on shares of Sunshine Biopharma in a research report on Thursday, December 5th.

About Sunshine Biopharma

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.